证券代码：002082 证券简称：万邦德 公告编号：2025-060 根据《中华人民共和国公司法》《关于新〈公司法〉配套制度规则实施相关 过渡期安排》及《上市公司章程指引》等相关法律、法规和规范性文件，公司拟 取消监事会和监事岗位，由董事会审计委员会行使《公司法》规定的监事会的职 权，公司《监事会议事规则》等监事会相关制度相应废止。 鉴于前述情况，公司同时根据《公司法》《深圳证券交易所股票上市规则》 《上市公司章程指引》等法律、法规及规范性文件的最新规定，拟对《公司章程》 相应条款进行修改： 1．将"股东大会"的表述统一调整为"股东会"，不再逐条列示。 2．将"经理""副经理"的表述统一调整为"总经理""副总经理"，不再 逐条列示。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第九届董事会第十八次会议，审议通过了《关于修订<公司章程>的议案》 及《关于制定、修订及废止公司部分治理制度的议案》，现将相关内容公告如下： 一、关于修订《公司章程》具体情况 3．其他非实质性修 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-061 万邦德医药控股集团股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第三次临时股东大会 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议时间： (4)公司董事会同意列席的相关人员。 8、会议地点：浙江省台州市温岭市城东街道百丈北路 28 号，公司行政楼 会议室。 二、会议审议事项 （1）现场会议时间：2025 年 11 月 17 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 11 月 17 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 20 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-058 万邦德医药控股集团股份有限公司 第九届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：9票同意，0票反对，0票弃权。 万邦德医药控股集团股份有限公司（以下简称"公司"）第九届董事会第十 八次会议通知于 2025 年 10 月 22 日以邮件、电话、微信等方式发出，会议于 2025 年 10 月 28 日在公司行政楼会议室以现场结合通讯方式召开。本次会议由董事长 赵守明先生主持，应出席会议董事 9 人，实际出席董事 9 人，韩彬先生、马健先 生、周岳江先生、李杨女士、屠鹏飞先生以通讯方式出席会议并参与表决。公司 监事及高级管理人员列席会议。会议的召集、召开及表决程序符合有关法律法规 和《公司章程》的规定。 本议案已经公司董事会审计委员会审议通过。 董事会审议认为：公司 2025 年第三季度报告的编制和审核程序符合相关法律 法规及公司相关制度的规定，报告内容真实、准确、完整地反映了公司的财务状 况和经营成果，不存在任何虚假记载、误导性 ...

Financial Performance - The company's revenue for Q3 2025 was CNY 439,154,394.07, representing a 36.51% increase compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 8,995,682.80, a decrease of 212.42% year-on-year[5]. - Total operating revenue for the current period was ¥1,017,706,438.36, a decrease of 5.1% compared to ¥1,074,491,139.98 in the previous period[24]. - The company's net profit for the current period is CNY 1,284,622.12, a significant decrease from CNY 36,246,556.95 in the previous period, representing a decline of approximately 96.45%[25]. - Operating profit for the current period is CNY 1,041,807.60, down from CNY 40,409,653.41 in the previous period, indicating a decrease of about 97.42%[25]. - The company's total comprehensive income for the current period is CNY 10,027,715.24, down from CNY 53,435,233.57 in the previous period, a decrease of approximately 81.24%[25]. - Basic and diluted earnings per share for the current period are both CNY 0.0100, a significant drop from CNY 0.0741 in the previous period[25]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was CNY 36,573,031.31, down 73.15% compared to the previous year[5]. - The company's cash and cash equivalents decreased from CNY 158,726,728.80 at the beginning of the period to CNY 83,070,795.97 at the end of the period, a decline of approximately 47.7%[20]. - Cash flow from operating activities for the current period is CNY 36,573,031.31, a decrease of 73.14% compared to CNY 136,224,725.34 in the previous period[26]. - Cash flow from investing activities shows a net outflow of CNY 287,768,022.83, worsening from a net outflow of CNY 193,233,025.70 in the previous period[27]. - Cash flow from financing activities resulted in a net inflow of CNY 179,098,407.90, compared to a net outflow of CNY 87,175,082.75 in the previous period, indicating a positive shift[27]. - The cash and cash equivalents at the end of the period amount to CNY 71,370,795.93, a slight decrease from CNY 73,766,560.85 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,541,970,797.02, an increase of 4.96% from the end of the previous year[5]. - Current assets totaled ¥1,742,675,531.54, a slight decrease from ¥1,803,320,380.71 in the previous period[21]. - Non-current assets increased to ¥2,799,295,265.48 from ¥2,524,076,699.82, reflecting a growth of 10.8%[21]. - Total liabilities rose to ¥1,775,399,359.75, compared to ¥1,570,954,359.63 in the previous period, indicating an increase of 13.0%[22]. - Total equity attributable to shareholders was ¥2,674,894,570.54, slightly up from ¥2,666,804,346.48[22]. - Long-term borrowings increased to ¥153,433,064.20 from ¥104,000,000.00, representing a growth of 47.5%[22]. - The company reported a decrease in short-term borrowings to ¥692,652,830.16 from ¥853,969,430.11, a reduction of 18.8%[22]. - Deferred tax assets increased to ¥150,623,375.37 from ¥134,444,446.98, showing a growth of 12.0%[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,415[12]. - The largest shareholder, Wanbangde Group Co., Ltd., holds 31.62% of the shares, with 153,150,000 shares pledged[12]. - The controlling shareholder and its concerted actors transferred a total of 60 million shares, accounting for 9.8089% of the company's total share capital, to a partnership on October 13, 2025[18]. - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending activities[18]. Research and Development - Research and development expenses increased by 34.25% to CNY 71,623,824.70, reflecting higher investment in innovative drug development[10]. - Wanbangde Pharmaceutical obtained invention patents for compositions and formulations for treating Alzheimer's disease and skin photoaging, as well as for a disulfide cyclic peptide compound and its preparation methods[14]. - The company completed the first subject enrollment for the Phase II/III clinical trial of the new drug Huperzine A controlled-release tablets for treating mild to moderate Alzheimer's disease[15]. - The Phase II/III clinical trial received ethical approval from the Capital Medical University Xuanwu Hospital's ethics review committee, allowing collaboration with over 50 research institutions nationwide[17]. Government Subsidies - The company reported a significant increase in government subsidies, with CNY 1,719,364.84 recognized in the current period[7]. Revenue and Costs - The company experienced a decline in revenue and net profit primarily due to the failure to win bids for key products in national procurement[5]. - Total operating costs for the current period were ¥1,058,426,407.78, down 1.7% from ¥1,077,232,284.96 in the previous period[24]. - Operating costs included ¥689,033,168.53 in operating expenses, which increased from ¥638,499,206.00 in the previous period[24]. - Total revenue from sales of goods and services received in cash is CNY 809,415,293.19, down from CNY 1,058,777,535.36, reflecting a decline of approximately 23.51%[26]. Accounts and Inventory - Accounts receivable increased from CNY 681,903,501.91 to CNY 728,378,485.73, reflecting a growth of about 6.8%[20]. - Inventory rose from CNY 213,858,705.73 to CNY 248,924,311.07, indicating an increase of approximately 16.4%[20]. - Prepayments increased from CNY 335,327,642.24 to CNY 374,423,888.23, representing an increase of about 11.6%[20]. - Other receivables increased significantly from CNY 18,567,129.32 to CNY 51,554,753.86, a growth of approximately 177.5%[20].

Core Viewpoint - The company’s subsidiary has received orphan drug designation from the FDA for WP203A (afamelanotide) to treat pemphigus, which is a rare autoimmune blistering disease [1][2]. Summary by Sections Qualification Recognition - The company submitted an application for orphan drug designation for WP203A to the FDA in August 2025, under application number DRU-2024-10630, and received confirmation of approval based on the Federal Food, Drug, and Cosmetic Act [1]. Drug Overview - Pemphigus is characterized by widespread blistering and erosion of the skin and mucous membranes, primarily affecting the elderly due to immune system dysfunction. Symptoms include severe itching, redness, and painful lesions, with the potential for life-threatening complications [1]. Impact of Orphan Drug Designation - The orphan drug designation for WP203A is expected to accelerate the company’s international drug development efforts. This designation provides various incentives, including tax credits for clinical trial costs, waiver of new drug application fees, and seven years of market exclusivity post-approval [2].

Core Insights - Wanbangde's subsidiary has made significant progress in the internationalization of its pemphigus treatment, successfully winning the first position in the 11th national drug procurement for its bromhexine hydrochloride injection [1] - The company submitted an orphan drug designation application for WP203A (alfanotide) to the FDA, which has been confirmed, marking a key step in its international strategy for pemphigus treatment [1][2] - Pemphigus is a rare autoimmune disease characterized by severe blistering and erosion of the skin and mucous membranes, primarily affecting the elderly [1][2] Industry Overview - The global prevalence of pemphigus is estimated to be between 1 to 50 cases per million, translating to approximately 70,000 to 2.1 million patients worldwide, with the most common type being pemphigus vulgaris [2] - Current treatments mainly involve corticosteroids and immunosuppressants, which have significant side effects, while biologics like rituximab and eculizumab are effective but expensive and require intravenous administration [2] - There are about 10 to 15 new drugs in clinical stages globally for pemphigus, including Wanbangde's WP203A [2] Regulatory and Market Implications - The orphan drug designation by the FDA provides various incentives for drug development, including tax credits for clinical trial costs, waiver of new drug application fees, and seven years of market exclusivity post-approval [2][3] - The global market for pemphigus drugs is expected to reach hundreds of billions of RMB, positioning the development of WP203A as a high-quality opportunity in the rare disease sector [3] - Wanbangde aims to transition from generic drugs to innovative drugs, with WP203A potentially becoming a significant player in the pemphigus treatment market due to its differentiated mechanism and international strategy [3]

人民财讯10月28日电，10月28日，万邦德（002082）制药集团扶健盐酸溴己新注射液以第一顺位成功中 选第十一批国家药品集采。 ...

Core Insights - Wanbangde's stock price increased by 2.51% on October 28, reaching 15.54 CNY per share, with a total market capitalization of 9.506 billion CNY [1] - The company has seen a year-to-date stock price increase of 141.68%, with a recent decline of 0.70% over the last five trading days [1] Financial Performance - For the first half of 2025, Wanbangde reported a revenue of 579 million CNY, a year-on-year decrease of 23.15%, and a net profit attributable to shareholders of 13.4635 million CNY, down 64.29% year-on-year [2] - The company has distributed a total of 613 million CNY in dividends since its A-share listing, with 122 million CNY distributed over the last three years [2] Shareholder Information - As of June 30, Wanbangde had 39,300 shareholders, an increase of 42.08% from the previous period, with an average of 14,085 circulating shares per shareholder, a decrease of 30.25% [2] Business Overview - Wanbangde, established on March 31, 1999, and listed on November 20, 2006, is primarily engaged in the production and sales of aluminum processing products, medical devices, and the research, production, and sales of modern Chinese medicine, chemical raw materials, and chemical preparations [1] - The revenue composition of Wanbangde includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [1] Market Activity - The company has appeared on the trading leaderboard seven times this year, with the most recent instance on October 13, where it recorded a net purchase of 6.4273 million CNY [1] - The net inflow of main funds on October 28 was 1.1317 million CNY, with large orders accounting for 21.37% of total purchases [1]

Group 1 - The core point of the article is that innovative drug developments and partnerships are shaping the competitive landscape in the pharmaceutical industry, with significant implications for market performance and patient care [1][2][4]. Group 2 - Xinda Biopharma's dual receptor agonist, Masitide, achieved primary endpoints in its Phase III clinical trial, demonstrating superior efficacy in blood sugar control and weight management compared to Semaglutide in Chinese patients with type 2 diabetes and obesity [1]. - Kangzhe Pharmaceutical signed an exclusive distribution agreement with Novartis for two ophthalmic drugs, which is expected to enhance the company's academic brand competitiveness and positively impact its performance [2]. - Sanbo Brain Science reported a 20% decrease in net profit for the first three quarters of 2025, despite a 20.26% increase in revenue, indicating potential challenges such as rising costs and market competition [3]. - Wanbangde's subsidiary received orphan drug designation from the FDA for WP203A, which is under development for treating pemphigus, providing the company with various regulatory advantages in the U.S. market [4].

Core Viewpoint - Wanbangde's subsidiary has received orphan drug designation from the FDA for WP203A (afamelanotide) to treat pemphigus, a rare autoimmune blistering disease, which may accelerate the company's international drug development efforts [1][3]. Group 1: FDA Orphan Drug Designation - The FDA granted orphan drug status to WP203A for the treatment of pemphigus, providing various incentives for drug development, including tax credits for clinical trial costs and a seven-year market exclusivity post-approval [1][2]. - Wanbangde submitted the orphan drug designation application for WP203A on August 2025, which was confirmed by the FDA [2]. Group 2: Mechanism and Current Treatment Landscape - Afamelanotide acts as a synthetic agonist of the MC1R receptor, demonstrating anti-inflammatory and immunomodulatory effects, and has been successfully used in treating erythropoietic protoporphyria (EPP) [2]. - Current treatments for pemphigus primarily include systemic corticosteroids and monoclonal antibodies, which have high relapse rates and severe side effects, indicating an unmet clinical need [2]. Group 3: Future Development and Uncertainties - Following the orphan drug designation, Wanbangde must conduct clinical trials for WP203A in accordance with FDA regulations, with uncertainties surrounding trial approval, results, and subsequent market application [3].